A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.

Abstract

OBJECTIVE:

To investigate the effects of 4-month treatment of medroxyprogesterone acetate (MPA) and Diane-35 on the clinical and biochemical features of hyperandrogenism and quality of life of adolescent girls with polycystic ovarian syndrome (PCOS).

DESIGN:

A prospective, randomized, cross-over study.

SETTING:

An accredited pediatric and adolescent gynecology clinic of a university-affiliated tertiary hospital.

PARTICIPANTS:

76 adolescents girls aged 14 to 19 years old with PCOS were recruited from July 2007 to July 2010.

INTERVENTIONS:

Girls were randomized into 2 groups. Group 1 received oral MPA for 4 months, followed by a washout period of 4 months, and then Diane-35 for another 4 months. Group 2 received the same combination but in the reverse order.

MAIN OUTCOME MEASURES:

Clinical and biochemical features of hyperandrogenism and quality of life were assessed.

RESULTS:

There was no significant difference between the 2 groups at baseline. No significant difference was found in the clinical and biochemical parameters of hyperandrogenism before and after treatment with MPA. Significant reduction of the acne score, LH/FSH ratio, and testosterone level was seen after taking Diane-35. Hirsutism was also improved but it did not reach statistical significant. When comparing post-MPA and post-Diane-35, the post-Diane-35 group had significantly improved acne score and LH/FSH ratio. No significant difference was found on quality of life between both groups after treatment.

CONCLUSION:

Diane-35 may be a more suitable treatment option in adolescent girls diagnosed with PCOS when compared to MPA.

• Authors: Jacqueline P W Chung, Alice K W Yiu, Tony K H Chung, Symphorosa S C Chan
• Journal: Journal of pediatric and adolescent gynecology (J Pediatr Adolesc Gynecol) Vol. 27 Issue 3 Pg. 166-71 (Jun 2014) ISSN: 1873-4332 [Electronic] United States
• PMID: 24656700 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: Copyright © 2014 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.

Chemical References

• Androgen Antagonists
• Drug Combinations
• Testosterone
• Ethinyl Estradiol
• Cyproterone Acetate
• Cyproterone acetate, ethinyl estradiol drug combination
• Luteinizing Hormone
• Follicle Stimulating Hormone
• Medroxyprogesterone Acetate

Topics

• Acne Vulgaris (drug therapy)
• Adolescent
• Androgen Antagonists (therapeutic use)
• Cross-Over Studies
• Cyproterone Acetate (therapeutic use)
• Drug Combinations
• Ethinyl Estradiol (therapeutic use)
• Female
• Follicle Stimulating Hormone (blood)
• Hirsutism (drug therapy)
• Humans
• Hyperandrogenism (blood, drug therapy, etiology)
• Luteinizing Hormone (blood)
• Medroxyprogesterone Acetate (therapeutic use)
• Polycystic Ovary Syndrome (blood, complications, drug therapy)
• Prospective Studies
• Quality of Life
• Severity of Illness Index
• Testosterone (blood)
• Young Adult